Clinical Trial Update: Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of abemaciclib in combination with letrozole for estrogen receptor-positive rare ovarian cancers. Recruitment is currently ongoing for conditions …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-type Granulosa Cell Tumor
• Low-grade Serous Ovarian Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)
• Letrozole (letrozole)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor | Phase 2 | Status: RECRUITING